Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease

• Príomhchruthaitheoirí: Niurys de Castro-Suárez (Údar), Mirjam N. Trame (Údar), Mayra Ramos-Suzarte (Údar), José M. Dávalos (Údar), Raymed A. Bacallao-Mendez (Údar), Anaelys R. Maceo-Sinabele (Údar), Víctor Mangas-Sanjuán (Údar), Gledys Reynaldo-Fernández (Údar), Leyanis Rodríguez-Vera (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2020-11-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic mo...